.: Leading On-Line Research Tool for Biomedical Intelligence :.
UserName: 
Password: 
 
Subscribe
Overview
Deal Statistics
MedTRACK Home


MedTRACK Brochure
Sample Deal Record
 

The MedTRACK Deals & Alliances database provides comprehensive coverage of licensing agreements and other deals by more than 22300 biomedical companies covered in MedTRACK. The MedTRACK D&A database is the industry leader for breadth and depth of deal coverage.

Search by

  • Company Name
  • Product name
  • Keyword
  • Product vs. technology
  • Royalties
  • Upfront payment
  • Equity investments
  • And more.

The MedTRACK Deals & Alliances database also contains the latest deal news, available SEC documents relating to each deal and a clickable list of the big dealmakers of recent months. Review the search categories below to see how a subscription to the MedTRACK Deals & Alliances database can support your analysis of opportunities in the biomedical sphere.


D&A Categories
Asset Purchase Co-Development
Co-Market Co-Promotion
Collaboration Commercialization
Development Distribution
Equity Joint Venture
Letter of Intent License
Manufacturing Marketing
Miscellaneous Option
Research Sales
Settlement Sublicense
Supply Termination



M&A Categories
Acquisition Acquisition Agreements
Acquisition of Assets Product Acquisition


Financial Terms
Credit Debt
Development Fees Equity
Fund License fees
Loan Milestone
Profit Sharing Royalty
Termination Fees Upfront Cash
Upfront Equity    



 
 
Deals Analyzed: 63,481

800 James Ave.
Suite 201
Scranton, PA 18510

telephone:
570-504-1800
fax:
570-961-2324



 
The information contained herein is based on sources believed to be reliable but is neither all-inclusive nor guaranteed by Life Science Analytics ("LSA"). Opinions, if any, reflect the judgment of LSA at this time and are subject to change. LSA does not undertake to advise you of changes in their opinion or information. Most of the companies LSA follows are emerging growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in the reports included in LSA's Database may be unsuitable for investors depending on their specific investment objectives, financial situation and needs. No report included in the LSA Database is a recommendation that any particular investor should purchase or sell any particular security in any amount or at all, and is not a solicitation of any offer to purchase or sell from or to any particular investor. For additional information that may be available on the securities mentioned, please contact Life Science Analytics.